Lexicon Pharmaceuticals (LXRX) Expected to Announce Quarterly Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Lexicon Pharmaceuticals to post earnings of ($0.06) per share and revenue of $4.14 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 37.53%. The firm had revenue of $0.69 million during the quarter, compared to the consensus estimate of $3.99 million. On average, analysts expect Lexicon Pharmaceuticals to post ($0.17) EPS for the current fiscal year and ($0.24) EPS for the next fiscal year.

Lexicon Pharmaceuticals Trading Up 0.7%

NASDAQ:LXRX opened at $1.49 on Thursday. The stock’s 50 day moving average price is $1.92 and its 200 day moving average price is $1.88. Lexicon Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $2.68. The company has a market capitalization of $662.98 million, a P/E ratio of -9.93 and a beta of 1.07. The company has a debt-to-equity ratio of 0.29, a quick ratio of 13.29 and a current ratio of 13.37.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on LXRX shares. Zacks Research lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 3rd. Wall Street Zen lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday, October 21st. Finally, Cantor Fitzgerald began coverage on shares of Lexicon Pharmaceuticals in a report on Monday, September 28th. They issued an “overweight” rating and a $8.00 price objective for the company. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Lexicon Pharmaceuticals has an average rating of “Hold” and an average price target of $5.70.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and chronic diseases. The company uses its drug discovery platform to identify small-molecule treatments designed to target specific biological pathways, with an emphasis on metabolic, cardiovascular and neurological conditions.

Lexicon’s commercial products include INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in certain adults with heart failure or type 2 diabetes and chronic kidney disease.